Single User License
INR 136740
Site License
INR 273480
Corporate User License
INR 410220

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Post-Traumatic Stress Disorder (PTSD)-Pipeline Review, H1 2015

Post-Traumatic Stress Disorder (PTSD)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Post-Traumatic Stress Disorder (PTSD)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Post-Traumatic Stress Disorder (PTSD)-Pipeline Review, H1 2015', provides an overview of the Post-Traumatic Stress Disorder (PTSD)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Post-Traumatic Stress Disorder (PTSD) Overview 9

Therapeutics Development 10

Pipeline Products for Post-Traumatic Stress Disorder (PTSD)-Overview 10

Pipeline Products for Post-Traumatic Stress Disorder (PTSD)-Comparative Analysis 11

Post-Traumatic Stress Disorder (PTSD)-Therapeutics under Development by Companies 12

Post-Traumatic Stress Disorder (PTSD)-Therapeutics under Investigation by Universities/Institutes 14

Post-Traumatic Stress Disorder (PTSD)-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Post-Traumatic Stress Disorder (PTSD)-Products under Development by Companies 19

Post-Traumatic Stress Disorder (PTSD)-Products under Investigation by Universities/Institutes 21

Post-Traumatic Stress Disorder (PTSD)-Companies Involved in Therapeutics Development 22

Addex Therapeutics Ltd 22

Azevan Pharmaceuticals, Inc. 23

Catalyst Pharmaceutical Partners, Inc. 24

Humanetics Corporation 25

Intra-Cellular Therapies, Inc. 26

Marinus Pharmaceuticals, Inc. 27

Nanotherapeutics, Inc. 28

Neuralstem, Inc. 29

Neurocrine Biosciences, Inc. 30

NeuroNascent, Inc. 31

Omeros Corporation 32

Otsuka Holdings Co., Ltd. 33

Polleo Pharma Limited 34

Tonix Pharmaceuticals Holding Corp. 35

Vanda Pharmaceuticals Inc. 36

Post-Traumatic Stress Disorder (PTSD)-Therapeutics Assessment 37

Assessment by Monotherapy Products 37

Assessment by Target 38

Assessment by Mechanism of Action 40

Assessment by Route of Administration 42

Assessment by Molecule Type 44

Drug Profiles 46

7-Keto-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

ADX-71743-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

brexpiprazole-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

CPP-115-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Drug for Post-Traumatic Stress Disorders-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Drugs to Inhibit FAAH for CNS Disorders-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

ganaxolone-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

iloperidone-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

ITI-007-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

NNI-351-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

NSI-189-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

NTC-942-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Rycal-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

S-107-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Small Molecule to Target GPR151 for CNS Diseases-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Small Molecule to Target GPR83 for CNS and Immunological Disorders-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Small Molecules for BED and PTSD-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Small Molecules for Post-Traumatic Stress Disorder-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Small Molecules to Antagonize TLR-4 for CNS Disorders-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

Small Molecules to Inhibit mGluR7 For Central Nervous System Disorders-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

SRX-246-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

SRX-251-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

TNX-102-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Vaccine for Post-Traumatic Stress Disorder and Depression-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

verucerfont-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

vigabatrin-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

ZL-006-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

Post-Traumatic Stress Disorder (PTSD)-Recent Pipeline Updates 86

Post-Traumatic Stress Disorder (PTSD)-Dormant Projects 106

Post-Traumatic Stress Disorder (PTSD)-Discontinued Products 107

Post-Traumatic Stress Disorder (PTSD)-Product Development Milestones 108

Featured News & Press Releases 108

Jun 10, 2014: Tonix Pharmaceuticals Receives IND Clearance From U.S. Food and Drug Administration for TNX-102 SL in Post-Traumatic Stress Disorder 108

Oct 11, 2013: Tonix Pharmaceuticals to Participate in the Women's Healthcare Innovation and Leadership Showcase on October 15, 2013 108

Aug 19, 2013: Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome 109

Oct 24, 2012: Tonix Pharma Completes Pre-IND Meeting With FDA For Potential New Treatment For Post-Traumatic Stress Disorder 109

Oct 15, 2012: Indiana University Scientists Discover New Drug For Preventing Post-Traumatic Stress Disorder 110

Aug 30, 2012: Armgo Pharma Announces Publication Of Data Related To New Approach For Treatment Of Stress-Induced Cognitive Disorders 110

May 23, 2012: Nanotherapeutics Initiates Phase II Clinical Trial Of PRX-3140 For Treatment Of Post Traumatic Stress Disorder 111

Jun 20, 2011: Neuralstem On Schedule To Complete Phase Ia Trial Of NSI-189 In Major Depression 112

Apr 21, 2011: Marinus Announces Commencement Of Phase II Trial Of Ganaxolone In Posttraumatic Stress Disorder 112

Apr 07, 2011: Marinus Receives US Patent For Ganaxolone 113

Appendix 114

Methodology 114

Coverage 114

Secondary Research 114

Primary Research 114

Expert Panel Validation 114

Contact Us 115

Disclaimer 115

List of Tables

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2015 10

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD)-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Comparative Analysis by Unknown Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Products under Investigation by Universities/Institutes, H1 2015 21

Post-Traumatic Stress Disorder (PTSD)-Pipeline by Addex Therapeutics Ltd, H1 2015 22

Post-Traumatic Stress Disorder (PTSD)-Pipeline by Azevan Pharmaceuticals, Inc., H1 2015 23

Post-Traumatic Stress Disorder (PTSD)-Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2015 24

Post-Traumatic Stress Disorder (PTSD)-Pipeline by Humanetics Corporation, H1 2015 25

Post-Traumatic Stress Disorder (PTSD)-Pipeline by Intra-Cellular Therapies, Inc., H1 2015 26

Post-Traumatic Stress Disorder (PTSD)-Pipeline by Marinus Pharmaceuticals, Inc., H1 2015 27

Post-Traumatic Stress Disorder (PTSD)-Pipeline by Nanotherapeutics, Inc., H1 2015 28

Post-Traumatic Stress Disorder (PTSD)-Pipeline by Neuralstem, Inc., H1 2015 29

Post-Traumatic Stress Disorder (PTSD)-Pipeline by Neurocrine Biosciences, Inc., H1 2015 30

Post-Traumatic Stress Disorder (PTSD)-Pipeline by NeuroNascent, Inc., H1 2015 31

Post-Traumatic Stress Disorder (PTSD)-Pipeline by Omeros Corporation, H1 2015 32

Post-Traumatic Stress Disorder (PTSD)-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 33

Post-Traumatic Stress Disorder (PTSD)-Pipeline by Polleo Pharma Limited, H1 2015 34

Post-Traumatic Stress Disorder (PTSD)-Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2015 35

Post-Traumatic Stress Disorder (PTSD)-Pipeline by Vanda Pharmaceuticals Inc., H1 2015 36

Assessment by Monotherapy Products, H1 2015 37

Number of Products by Stage and Target, H1 2015 39

Number of Products by Stage and Mechanism of Action, H1 2015 41

Number of Products by Stage and Route of Administration, H1 2015 43

Number of Products by Stage and Molecule Type, H1 2015 45

Post-Traumatic Stress Disorder (PTSD) Therapeutics-Recent Pipeline Updates, H1 2015 86

Post-Traumatic Stress Disorder (PTSD)-Dormant Projects, H1 2015 106

Post-Traumatic Stress Disorder (PTSD)-Discontinued Products, H1 2015 107

List of Figures

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2015 10

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD)-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 37

Number of Products by Top 10 Targets, H1 2015 38

Number of Products by Stage and Top 10 Targets, H1 2015 38

Number of Products by Top 10 Mechanism of Actions, H1 2015 40

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 40

Number of Products by Top 10 Routes of Administration, H1 2015 42

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 43

Number of Products by Top 10 Molecule Types, H1 2015 44

Number of Products by Stage and Top 10 Molecule Types, H1 2015 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Addex Therapeutics Ltd

Azevan Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners, Inc.

Humanetics Corporation

Intra-Cellular Therapies, Inc.

Marinus Pharmaceuticals, Inc.

Nanotherapeutics, Inc.

Neuralstem, Inc.

Neurocrine Biosciences, Inc.

NeuroNascent, Inc.

Omeros Corporation

Otsuka Holdings Co., Ltd.

Polleo Pharma Limited

Tonix Pharmaceuticals Holding Corp.

Vanda Pharmaceuticals Inc.

Post-Traumatic Stress Disorder (PTSD) Therapeutic Products under Development, Key Players in Post-Traumatic Stress Disorder (PTSD) Therapeutics, Post-Traumatic Stress Disorder (PTSD) Pipeline Overview, Post-Traumatic Stress Disorder (PTSD) Pipeline, Post-Traumatic Stress Disorder (PTSD) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com